And the way I see it, for non respiratory indications, Mesoblast may spend up to 50% on development then, subject to marketing approvals, in those instances also gets 50% of profit, possibly more $ than the usually mentioned double digit sales royalty agreement.
Cell Therapy News/Articles, page-8783
-
- There are more pages in this discussion • 9,038 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.005(0.43%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $3.351M | 2.869M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 57525 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 108814 | 24 |
View Market Depth
| Last trade - 15.13pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |